MedTrace Logo

Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer

NCT01817738 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2017-02-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether the new RNActive®-derived prostate cancer vaccine CV9104 prolongs survival in patients with asymptomatic or minimally symptomatic metastatic prostate cancer that is castrate resistant.

Conditions

Interventions

BIOLOGICAL

CV9104

Intradermal injection of CV9104

BIOLOGICAL

Placebo

Intradermal injection of placebo

Sponsors & Collaborators

  • CureVac

    lead INDUSTRY

Principal Investigators

  • Arnulf Stenzl, Prof. Dr. · University Hospital of Tübingen; Dept. of Urology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2016-08-31
Completion
2017-01-31

Countries

  • Czechia
  • France
  • Germany
  • Poland
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01817738 on ClinicalTrials.gov